Axillary hyperhidrosis: treatment with botulinum toxin A. 1998

I R Odderson
Department of Rehabilitation Medicine, University of Washington, Seattle, USA.

Hyperhidrosis can be emotionally challenging and socially and professionally disruptive, and there are few effective treatments. This condition was successfully treated with botulinum toxin in two men who, since their early teens, had had excessive axillary sweating, requiring frequent shirt changes. They received bilateral axillary injections with 100 units of botulinum toxin type A, and within 5 days reported cessation of excessive sweating. Quantitative measurements before and 2 to 4 weeks after the injections demonstrated an average reduction of 71% and 76% (from 11.6 to 3.4 and from 2.5 to 0.6 mL/min m2) in axillary sweating during rest. A 96% reduction (from 42.9 to 1.7 mL/min m2) was seen in one patient during mental stress. No complications developed. This study quantitates the reduced axillary sweating achieved through chemodenervation with botulinum toxin A.

UI MeSH Term Description Entries
D008297 Male Males
D009465 Neuromuscular Agents Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS. Skeletal Muscle Relaxants,Neuromuscular Effect,Neuromuscular Effects,Agents, Neuromuscular,Effect, Neuromuscular,Effects, Neuromuscular,Muscle Relaxants, Skeletal,Relaxants, Skeletal Muscle
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006945 Hyperhidrosis Excessive sweating. In the localized type, the most frequent sites are the palms, soles, axillae, inguinal folds, and the perineal area. Its chief cause is thought to be emotional. Generalized hyperhidrosis may be induced by a hot, humid environment, by fever, or by vigorous exercise. Hyperidrosis
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001365 Axilla Area of the human body underneath the SHOULDER JOINT, also known as the armpit or underarm. Armpit,Underarm
D013563 Sympathectomy, Chemical Sympathectomy using chemicals (e.g., 6-hydroxydopamine or guanethidine) which selectively and reversibly destroy adrenergic nerve endings while leaving cholinergic nerve endings intact. Chemosympathectomy,Denervation, Sympathetic, Chemical,Chemical Sympathectomy,Chemical Sympathetic Denervation,Sympathetic Denervation, Chemical,Chemical Sympathectomies,Chemical Sympathetic Denervations,Chemosympathectomies,Denervation, Chemical Sympathetic,Denervations, Chemical Sympathetic,Sympathectomies, Chemical,Sympathetic Denervations, Chemical
D019274 Botulinum Toxins, Type A A serotype of botulinum toxins that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25. Botulinum Neurotoxin Type A,Botulinum Toxin A,Botulinum Toxin Type A,Botox,Botulinum A Toxin,Botulinum Neurotoxin A,Clostridium Botulinum Toxin Type A,Clostridium botulinum A Toxin,Meditoxin,Neuronox,Oculinum,Onabotulinumtoxin A,OnabotulinumtoxinA,Vistabel,Vistabex,Neurotoxin A, Botulinum,Toxin A, Botulinum,Toxin, Botulinum A

Related Publications

I R Odderson
July 2002, International journal of dermatology,
I R Odderson
February 1998, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
I R Odderson
October 2014, Dermatologic clinics,
I R Odderson
January 2000, Aesthetic plastic surgery,
I R Odderson
July 1996, Clinical and experimental dermatology,
I R Odderson
March 2002, Journal of the European Academy of Dermatology and Venereology : JEADV,
I R Odderson
August 2009, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery,
I R Odderson
September 2004, The Medical letter on drugs and therapeutics,
I R Odderson
February 2001, The New England journal of medicine,
Copied contents to your clipboard!